Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: Study protocol of a randomised, double-blinded, placebo-controlled clinical trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence : Study protocol of a randomised, double-blinded, placebo-controlled clinical trial. / Antonsen, Kerstin K; Klausen, Mette K; Brunchmann, Amanda S; le Dous, Nina; Jensen, Mathias E; Miskowiak, Kamilla Woznica; Fisher, Patrick M; Thomsen, Gerda K; Rindom, Henrik; Fahmy, Thomas P; Vollstaedt-Klein, Sabine; Benveniste, Helene; Volkow, Nora D; Becker, Ulrik; Ekstrøm, Claus; Knudsen, Gitte Moos; Vilsbøll, Tina; Fink-Jensen, Anders.
In: BMJ Open, Vol. 8, No. 7, e019562, 09.2018.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence
T2 - Study protocol of a randomised, double-blinded, placebo-controlled clinical trial
AU - Antonsen, Kerstin K
AU - Klausen, Mette K
AU - Brunchmann, Amanda S
AU - le Dous, Nina
AU - Jensen, Mathias E
AU - Miskowiak, Kamilla Woznica
AU - Fisher, Patrick M
AU - Thomsen, Gerda K
AU - Rindom, Henrik
AU - Fahmy, Thomas P
AU - Vollstaedt-Klein, Sabine
AU - Benveniste, Helene
AU - Volkow, Nora D
AU - Becker, Ulrik
AU - Ekstrøm, Claus
AU - Knudsen, Gitte Moos
AU - Vilsbøll, Tina
AU - Fink-Jensen, Anders
N1 - © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
PY - 2018/9
Y1 - 2018/9
N2 - INTRODUCTION: Alcohol dependence is a major public health problem. It is underdiagnosed and undertreated. Even when treated, more than 2/3 of patients in abstinence-oriented treatment will relapse within the first year. Thus, there is an urgent need for efficacious medical treatment of alcohol dependence. Glucagon-like peptide-1 (GLP-1) receptor stimulation has proven to reduce alcohol consumption in preclinical experiments. However, the effect of GLP-1 receptor agonists in humans has to our knowledge, not yet been investigated. METHODS AND ANALYSIS: Design, participants and intervention: The effect of the once-weekly GLP-1-receptor-agonist exenatide will be investigated in a double-blinded, placebo-controlled, randomised clinical trial. 114 outpatients will be recruited and randomised to treatment with either placebo or exenatide once weekly for 26 weeks as a supplement to cognitive-behavioural therapy. The primary endpoint is reduction in number of 'heavy drinking days'. The secondary endpoints include changes in total alcohol consumption, days without consumption, changes in brain activity and function, smoking status, cognition, measures of quality of life and changes in phosphatidylethanol as a biomarker of alcohol consumption from baseline to follow-up at week 26. Status: Currently recruiting patients.ETHICS AND DISSEMINATION: Ethical approval has been obtained. Before screening, all patients will be provided oral and written information about the trial. The study results will be disseminated by peer-review publications and conference presentations and has the potential to reveal a completely new medical treatment of alcohol dependence.
AB - INTRODUCTION: Alcohol dependence is a major public health problem. It is underdiagnosed and undertreated. Even when treated, more than 2/3 of patients in abstinence-oriented treatment will relapse within the first year. Thus, there is an urgent need for efficacious medical treatment of alcohol dependence. Glucagon-like peptide-1 (GLP-1) receptor stimulation has proven to reduce alcohol consumption in preclinical experiments. However, the effect of GLP-1 receptor agonists in humans has to our knowledge, not yet been investigated. METHODS AND ANALYSIS: Design, participants and intervention: The effect of the once-weekly GLP-1-receptor-agonist exenatide will be investigated in a double-blinded, placebo-controlled, randomised clinical trial. 114 outpatients will be recruited and randomised to treatment with either placebo or exenatide once weekly for 26 weeks as a supplement to cognitive-behavioural therapy. The primary endpoint is reduction in number of 'heavy drinking days'. The secondary endpoints include changes in total alcohol consumption, days without consumption, changes in brain activity and function, smoking status, cognition, measures of quality of life and changes in phosphatidylethanol as a biomarker of alcohol consumption from baseline to follow-up at week 26. Status: Currently recruiting patients.ETHICS AND DISSEMINATION: Ethical approval has been obtained. Before screening, all patients will be provided oral and written information about the trial. The study results will be disseminated by peer-review publications and conference presentations and has the potential to reveal a completely new medical treatment of alcohol dependence.
KW - alcohol dependence
KW - clinical pharmacology
KW - glp-1
KW - glucagon-like peptide 1
KW - magnetic resonance imaging
KW - nuclear radiology
U2 - 10.1136/bmjopen-2017-019562
DO - 10.1136/bmjopen-2017-019562
M3 - Journal article
C2 - 30012779
VL - 8
JO - BMJ Open
JF - BMJ Open
SN - 2044-6055
IS - 7
M1 - e019562
ER -
ID: 203086117